Of sophists and spin-doctors: Industry-sponsored ghostwriting and the crisis of academic medicine

Mens Sana Monographs

Volumn 8, Issue 1, 2010, Pages 129-145

  McHenry, Leemon ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Academic medicine; Ghostwriting; Key opinion Leader; Medical education and communication companies; Pharmaceutical industry; Publications strategy; Sophists

Indexed keywords

EID: 75649146682     PISSN: 09731229     EISSN: 19984014     Source Type: Journal    
DOI: 10.4103/0973-1229.58824     Document Type: Article

References (46)

1. Armstrong D., (2006), Medical Journal to Issue Correction on Review of Depression Treatment, Wall Street Journal, July 18, online.wsj.com/article/ SB115322997681109756.html (Last accessed Dec 2009)
2. Barnett A., (2003), Revealed: How Drug Firms 'Hoodwink' Medical Journals, Guardian, December 7, www.guardian.co.uk/society/2003/dec/07/health. businessofresearch (Last accessed Dec 2009)
3. Berenson, A., (2005), Evidence in Vioxx Suits Shows Intervention by Merck Officials, New York Times, April 24, www.nytimes.com/2005/04/24/business/ 24drug.html (Last accessed Dec 2009)
4. Chan A-W, Hróbjartsson A., Haahr M. T., Gøtzsche P.C., Altman D. G., (2004), Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials: Comparison of Protocols to Published Articles, JAMA, 291, p2457-2465.
5. Fugh-Berman A., (2005), The Corporate Coauthor, J Gen Intern Med, 20, p547.
6. Elliott, C. (2001), Pharma Buys a Conscience. The American Prospect, 12, p16-20.
7. Elliott, C., (2004), Pharma Goes to the Laundry: Public Relations and the Business of Medical Education, Hast Cent Rep, 34, p18-23.
8. Golden, G.A., Parochka, J. N., Overstreet, K. M., (2002), Medical Education and Communication Companies: An Updated In-Depth Profile, Journal of Continuing Education in the Health Professions, 22, p55-62.
9. Graham, D. J., D. Campen, R. Hui, M. Spence, C. Cheetham, G. Levy, S. Shoor, W. A. Ray., (2005), Risk of Acute Mycardial Infarction and Sudden Cardiac Death in Patients Treated with Cyclo-Oxygenase 2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs: Nested Case-Control Study, Lancet, 365, p480.
10. Healy, D., Cattell, D., (2003), Interface Between Authorship, Industry and Science in the Domain of Therapeutics, Br J Psychiatry, 183, p22-27.
11. Healy, D., (2008), Our Censored Journals, Mens Sana Monographs, 6, p.244-256.
12. Hill, M., (2009), Ghosts in the Medical Machine, Philadelphia Inquirer, September 20. Available at: www.philly.com/philly/business/homepage/20090920- Ghosts-in-the-medical-machine. html?&subscribe=y&listID=1441&action= logIn (Last accessed Dec 2009)
13. Holden, C., (2006), Scientific Publishing: The Undisclosed Background of a Paper on a Depression Treatment, Science, 313, p598-599.
14. Horton R., (2004), The Dawn of McScience, NY Rev Books, 51(4), p7-9.
15. House of Commons Health Committee, (2005), The Influence of the Pharmaceutical Industry, Vol.1. London: The Stationary Office.
16. International Committee of Medical Journal Editors, (ICMJE), (2001), International Committee of Medical Journal Editors Website. Available at: www.icmje.org/ethical-1author. html (Last accessed Oct 2009).
17. Jacobs, A., Wager, E., (2005), European Medical Writers Association (EMWA) Guidelines on the Role of Medical Writers in Developing Peer-Reviewed Publications. Current Medical Research Opinion, 21, p317-321. (Pubitemid 40469909)
18. Jureidini, J., McHenry, L., Mansfield, P., (2008), Clinical Trials and Drug Promotion: Selective Reporting of Study 329, Int J Risk Saf Med, 20, p73-81.
19. Keller, M. B., Ryan, N. D., Strober, M., Klein, R. G., Kutcher, S. P, Birmaher, B., et al., (2001), Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial. J Am Acad Child Adolesc Psychiatry, 40, p762-772.
20. Langdon-Neuner, E., (2008), Medical GhostWriting, Mens Sana Monographs, 6, p257-273.
21. Lexchin, J., Light, D W., (2006), Commercial Influence and the Content of Medical Journals, BMJ, 332, p1444-1447.
22. Lisse, J. R., Perlman, M., Johansson, G., Shoemaker, J. R., Schechtman, J., Skalky, C. S., Dixon, M. E., et al., (2003), Gastrointestinal Tolerabilty and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthrtis, Ann InterMed, 139, p539-546.
23. McHenry, L., (2005), On the Origin of Great Ideas: Science and the Age of Big Pharma. Hast Cent Rep, 35, p17-19.
24. McHenry, L., (2007), Commercial Influences on the Pursuit of Wisdom, London Review of Education, 5, 131-142.
25. McHenry, L., (2008), Biomedical Research and Corporate Interests: A Question of Academic Freedom, Mens Sana Monographs, 6, p.146-156.
26. McHenry, L., Jureidini, J., (2008), Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study, Accountability in Research, 15, p152-167.
27. Moffatt, B., Elliott, C., (2007), Ghost Marketing: Pharmaceutical Companies and Ghostwritten Journal Articles, Perspectives in Biology and Medicine, 50, p18-31.
28. Moynihan, R., Cassels, A., (2005), Selling Sickness: How The World's Biggest Pharmaceutical Companies are Turning Us All Into Patients, New York: Nation Books.
29. Mundy, A., (2001), Dispensing with the Truth: The Victims, the Drug Companies, and the Dramatic Story Behind the Battle over Fen-Phen, New York: St. Martin's Press.
30. Nemeroff, C. B., (ed) (2003), Advancing the Treatment of Mood and Anxiety Disorders: The First 10 Years' Experience with Paroxetine, Psychopharmacology Bulletin, 37, p6-177.
31. Nemeroff, C. B., Mayberg, H. S., Krahl, S. E., et al., (2006), VNS Therapy in Treatment- Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms, Neuropsychopharmacology, 31, p1345-1355.
32. Ngai, S., Gold, J. L., Gill, S. S., Rochon, P.A., (2005), Haunted Manuscripts: Ghost Authorship in the Medical Literature, Accountability in Research, 12, p103-114.
33. Petersen, M., (2002), Madison Ave. Plays Growing Role in Drug Research. New York Times, November 22. Available at: www.nytimes.com/2002/11/22/business/ 22DRUG. html?pagewanted=5 (Last accessed Dec 2009)
34. Perrone, M., (2009), Glaxo Used Ghostwriting Program to Promote Paxil. The Boston Globe, August 19, www.boston.com/news/nation/articles/2009/08/20/ glaxosmithkline-used- ghostwriting-to-promote-paxil (Last accessed Dec 2009)
35. Pollock, B., (1998), Discontinuation Symptoms and SSRIs, J. Clin. Psychiatry, 10, p535-536.
36. Rees, S.T., (2003), Who Actually Wrote the Research Paper? How to Find Out, June 12, BMJ Rapid Responses, www.bmj.com/cgi/eletters/326/7400/1202#3366 (Last accessed Oct, 2009).
37. Ross, J. S., Hill, K. P., Egilman, D. S., Krumholz, H. M., (2008), Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation, JAMA, 299, p1800-1812.
38. Safer, D. J., (2002), Design and Reporting Modifications in Industry-Sponsored Comparative Psychopharmacology Trials, The Journal of Nervous and Mental Disease, 190, p583-592.
39. Singer, N., (2009), Medical Papers by Ghostwriters Pushed Therapy, New York Times, August 5, www.nytimes.com/2009/08/05/health/research/05ghost.html?- r=1 (Last accessed Dec 2009)
40. Sismondo, S., (2008), Ghosts in the Machine: Publication Planning in the Medical Sciences. Social Studies of Science, 39, p171-198.
41. Smith, R., (2005), Medical Journals are an Extension of the Marketing Arm of Pharmaceutical Companies. PloS Med, 2: e138.
42. Steinman, M. A., Bero, L. A., Chren, M. M., et al., (2006), Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents, Ann Inter Med, 145, p284-293.
43. Scientific Therapeutics Information, Inc., (STI), (2006), Scientific Therapeutics Information, Inc. Website, www.stimedinfo.com. (Last Accessed March 2006) [Author's note: This is not how it is in Oct 2009 since they have watered down their promotional mission after their role in several ghostwriting scandals was revealed. But I have a print out of the site from 2006 with the quotation and it is correct.]
44. Sullivan, T., (2009), Ghost Writing: Casper, Congress and NIH. www.policymed.com (Last Accessed August 2009).
45. Wager, E., (2007), What Medical Writing Means to Me, Mens Sana Monographs, 5, p.169-177.
46. World Association of Medical Editors (WAME), (2005), World Association of Medical Editors Website, www.wame.org (Last accessed May 2005). [Author's note: This website has been updated since 2005. I cannot fi nd this statement on the website now, but I do have a print-out of the site in 2005 and have verifi ed that it is correct.]